Howard Marks
Oaktree Capital Management
Howard Marks AFTERNEXT HEALTHTECH ACQUISI stake
total: 853
Oaktree Capital Management AFTRU trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q4
According to 2026 Q2 report, Howard Marks doesn't hold any AFTERNEXT HEALTHTECH ACQUISI (AFTRU) shares. To date, the estimated cost basis is nearly $9.96 for "buy" trades and estimated average "sell" price is $9.96. Oaktree Capital Management first purchased AFTRU in 2021 Q3, initially acquiring 150,000 shares. Since the initial investment in AFTERNEXT HEALTHTECH ACQUISI (AFTRU), Oaktree Capital Management has made 1 more transaction.
When did Howard Marks sell AFTERNEXT HEALTHTECH ACQUISI (AFTRU)?
Howard Marks sold off the entire AFTERNEXT HEALTHTECH ACQUISI (AFTRU) position in 2021 Q4.
When did Howard Marks buy AFTERNEXT HEALTHTECH ACQUISI (AFTRU)?
Howard Marks first invested in AFTERNEXT HEALTHTECH ACQUISI (AFTRU) in 2021 Q3 at the reported quarter-end price of $9.96 per share.
What's the cost basis of Oaktree Capital Management's AFTRU stake?
The estimated cost basis for AFTERNEXT HEALTHTECH ACQUISI (AFTRU) stake is around $9.96 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $9.96
- Weighted AVG sell price:
- $9.96
Howard Marks's historical trades in AFTERNEXT HEALTHTECH ACQUISI
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q4
|
0.00%
|
0
|
$9.96
|
|
-100% (-150,000)
|
-0.02%
|
|
2021 Q3
|
0.02%
|
150,000
|
$9.96
|
$1,494,000
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.